CONTENTS

Page No.

List of tables
List of figures
Preface i - viii

CHAPTER-1: 1 - 28
Introduction to

➢ Impact of various impurities on quality safety and efficacy of cancer and hypertensive active pharmaceutical ingredients

➢ Strategies for impurities in Pharmaceutical products

➢ Analytical Methods, stability indicative Importance & Requirement

CHAPTER-2: 29 - 52
Theoretical principles of UPLC/LCMS techniques employed in the identification and quantification of impurities in anticancer Active Pharmaceutical Ingredients (APIs).

CHAPTER-3: 53 -76
Literature Survey on identification and quantification of impurities in Active Pharmaceutical ingredients employing UPLC/LCMS analytical methods and scope of the study
CHAPTER 4
Identification of degradant impurity in Gefitinib by using validated rapid resolution Liquid Chromatography (RRLC) Method

CHAPTER 5:
Stability Indicative, validated, fast HPLC method for quantification of two genotoxic impurities in Imatinib Mesylate

CHAPTER 6:
A validated stability indicating UFLC method for Bortezomib in the presence of degradation products and its process related impurities

CHAPTER 7:
Degradation pathway for Eplerenone by Validated Stability Indicating UP-LC method

CHAPTER 8:
A validated stability indicative UP-LC method for Nilotinib Hydrochloride for the determination of process related and degradation impurities